

**Purpose:** To determine the rates of neutropenia, neutropenic sepsis and mortality within 30 days of chemotherapy in patients receiving up-front docetaxel for hormone-naïve metastatic prostate cancer or selected locally advanced prostate cancer at the Edinburgh Cancer Centre (ECC).

**Methods:** 68 patients received up-front docetaxel at ECC between July 2015 and June 2017 for the indications above. 11 patients had locally advanced disease. Using TRAK and Chemocare software, the date of diagnosis, performance status, TNM staging, Gleason grade and pre-treatment PSA (where available) were recorded. The number of cycles of docetaxel received, number of delayed cycles, dose reductions, rates of hospitalisation within 30 days of chemotherapy, neutropenia, neutropenic sepsis and mortality within 30 days of chemotherapy were recorded.

**Results:** The median time to starting chemotherapy after ADT was 63 days (IQR = 53–83), 16 patients started after 12 weeks. The full 6 cycles of docetaxel were given to 83.8% ( $n = 57/68$ ) of patients. A dose reduction was required in 26.5% ( $n = 18/68$ ). Neutropenia was recorded in 38.2% ( $n = 26/68$ ) and 20.6% ( $n = 14/68$ ) were treated for neutropenic sepsis. Of these patients, 8 went on to complete the planned 6 cycles of docetaxel. 2.9% ( $n = 2/68$ ) died within 30 days of receiving chemotherapy; both had metastatic disease. Therefore, in our cohort 14.3% ( $n = 2/14$ ) of patients who developed neutropenic sepsis died.

**Conclusion:** Up-front docetaxel for the management of metastatic and selected locally advanced prostate is generally well-tolerated, with most patients completing 6 cycles of treatment; however, 26.5% required a dose reduction and 16.2% did not complete chemotherapy. A significant proportion developed neutropenic sepsis, with 2 deaths related to treatment. Pending cost analysis, prophylactic GCSF for this cohort of patients should be considered. We intend to evaluate progression-free survival to compare our data with that of the published trials.

#### Variability Analysis of Clinical Target Volume Outlining for Prostate Stereotactic Body Radiotherapy within the Multicentre PACE Trial

K. Morrison, O. Naismith, N. van As

Royal Marsden Hospital, London, UK

**Purpose:** The PACE trial is a randomised multicentre trial comparing stereotactic body radiotherapy (SBRT) with conventional treatment in low- and intermediate-risk prostate cancer. SBRT is associated with a small margin for error, and it is therefore vital to ensure accuracy of clinical target volume (CTV) delineation. As part of the PACE trial quality assurance programme, centres are required to successfully complete a benchmark planning exercise using CT and MRI from a set intermediate-risk cases. The aim of this study was to analyse CTV outlining variability between centres.

**Methods:** Imaging and structure sets from 21 centres were uploaded using VODCA (Visualisation and Organisation of Data for Cancer Analysis) software. The investigational CTV, prostate and proximal seminal vesicles (pSV) contours were compared with reference PACE volumes using conformity indices [1–3]: DICE similarity coefficient; Geographical Miss Index (GMI); and Disconcordance Index (DI).

**Results:** The median volumes of the investigational CTV, prostate and pSV contours were greater than the reference contours by 9.7 cm<sup>3</sup>, 7.7 cm<sup>3</sup> and 1.7 cm<sup>3</sup>, respectively. The median DICE coefficient (ideal value 1) was 0.72 (0.39–0.86) for pSV contouring, compared with 0.88 (0.82–0.91) for CTV and 0.905 (0.87–0.93) for prostate contouring, demonstrating that pSV contours had the least similarity to reference contours. The level of geographical miss was relatively low, reflected by low median GMI: CTV 0.06 (0.01–0.15), prostate 0.03 (0.01–0.09), pSV 0.15 (0.03–0.66). Median DI values were higher: CTV 0.17 (0.07–0.23), prostate 0.15 (0.04–0.22), pSV 0.31 (0.03–0.62), demonstrating that, overall, investigational contours were excessive compared with reference contours, particularly for pSV contouring.

**Conclusion:** The use of conformity indices has shown that CTV contouring variability between centres in the PACE trial is most evident with regard to pSV delineation. This highlights the need for a standard pSV delineation method to improve consistency in further prostate SBRT trials.

#### References

- [1] Hanna GG, Hounsell AR, O'Sullivan JM. Geometrical analysis of radiotherapy target volume delineation: a systematic review of reported comparison methods. *Clin Oncol* 2010;22(7):515–25.
- [2] Holyoake DLP, Robinson M, Grose D, McIntosh D, Sebag-Montefiore D, Radhakrishna G et al. Conformity analysis to demonstrate reproducibility of

target volumes for Margin-Intense Stereotactic Radiotherapy for borderline-resectable pancreatic cancer. *Radiother Oncol* 2016;121(1):86–91.

[3] Gwynne S, Spezi E, Wills L, Nixon L, Hurt C, Joseph G et al. Toward semi-automated assessment of target volume delineation in radiotherapy trials: the SCOPE 1 pretrial test case. *Int J Radiat Oncol Biol Phys* 2012;84(4):1037–42.

#### Less to Hold – a Comparison of Bowel and Bladder Toxicities in Patients Undergoing Prostate Radiotherapy between those Treated with an Empty Bladder and those Following a Bladder Filling Protocol

S. Morrison\*, T. Ellis\*, E. Fillingham\*, Y.P. Song†, A. Birtle\*

\*Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK

†Christie Hospital NHS Foundation Trust, Manchester, UK

**Purpose:** Radical radiotherapy to the prostate is conventionally treated with a full bladder to minimise dose to bladder and bowel. Patients' tolerance of the bladder filling protocol varies and 'accidents' during treatment can cause undue distress to patients and increased pressure on the radiotherapy department. Several UK centres report treating with an empty bladder. We carried out a feasibility study of full bladder versus empty bladder to ascertain if we can safely change our practice.

**Methods:** 50 patients receiving radical radiotherapy to the prostate were randomised in a 1:1 manner to control and empty bladder groups. The control group followed the conventional drinking protocol at our centre (200 ml pre-treatment) and the empty bladder group was instructed to void prior to treatment. Baseline, end of treatment and 6 week follow-up scores were prospectively collected for IPSS, LENT SOMA bowel toxicity and quality of life questionnaires. Bowel and bladder DVH achievements were assessed.

**Results:** 50 patients were enrolled between March 2017 and January 2018. The mean increase in IPSS score from baseline to end of treatment was 2.12 for patients on the drinking protocol and 3.22 for those on the empty bladder protocol; this was not statistically significant ( $P = 0.68$ ). At 6 weeks of follow-up, mean IPSS scores improved compared with baseline in the control group (–0.33) but worsened (+2.86) in the empty bladder group. This was once again not statistically significant ( $P = 0.08$ ). No difference was seen in bowel toxicity, quality of life or dose to OARs between the 2 groups.

**Conclusion:** An empty bladder approach in prostate radiotherapy has no significant difference on acute bowel and bladder toxicity or OAR dose constraints. Empty bladder treatment can improve patient comfort and efficiency in our department. We continue to monitor patients in order to determine impact on long-term toxicity.

#### A Phase II Trial of Triamcinolone with Hormone Therapy for Prostate Cancer (TRICREST) in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer

K. Ng, S.-J. Sarker, M. Greenwood, E. Gjafa, C. Alifrangis, J. Shamash  
St Bartholomew's Hospital, London, UK

**Purpose:** To evaluate the efficacy of intramuscular triamcinolone in chemotherapy-naïve metastatic castration resistant prostate cancer (CRPC).

**Methods:** We conducted a phase II study of intramuscular triamcinolone administered monthly in metastatic CRPC. Triamcinolone has putative advantages over commonly used steroids, including lack of weight gain and an inability to stimulate mutated androgen receptors. 55 patients were recruited over 2012–2016. Imaging was performed every 3 months. The primary end point was radiological and symptomatic progression-free survival (PFS). Secondary end points included PSA progression, weight changes and toxicity. Steroid androgenic precursors, cortisol and circulating tumour cells were assessed prior to and 1 month after triamcinolone to see if they correlated with PFS.

**Results:** Median follow-up time was 21.3 months (95%CI: 13.2–24.5). The median radiological PFS was 9.4 months (95%CI: 7.0–20.1) and the 6 month PFS rate was 67.3% (95%CI: 0.53–0.78). The 50% PSA response rate was 31/55 = 56% (95%CI: 42–70%). There were no treatment-related deaths. The most common grade 3 toxicity was hypertension 40%, but only 5 patients (11%) required concomitant medication. Proximal myopathy (grade 2) was seen in 22 patients (40%). Skin toxicity (grade 2; bruising) was seen in 7 patients (12%). One patient had a gastrointestinal bleed. Hyperglycaemia developed in 3 patients (5%) There was no evidence of weight gain (mean weight 83.5 kg pre-study and 79.4 kg post-study).

**Conclusion:** Intramuscular triamcinolone is an effective second-line hormonal agent in CRPC. Its side-effect profile is different from other steroids and has the advantage of supervised administration.

#### Varying Atlas Numbers and Imaging Modality for Auto-contouring in Prostate Radiotherapy

A. Pathmanathan\*, J. Kieselmann\*, D. Brand\*, J. Christodouleas†, S. Nill\*, R. Huddart\*

\*Institute of Cancer Research/The Royal Marsden NHS Foundation Trust, London, UK

†Elekta Inc./Hospital of the University of Pennsylvania, Philadelphia, PA, USA

**Purpose:** Auto-contouring reduces clinician delineation time and improves interobserver variability [1], particularly relevant in adaptive radiotherapy (RT) [2]. Here we assess the impact of atlas number and imaging modality on the quality and speed of a machine learning-based prostate auto-contouring research tool (ADMIRE, v2.0, Elekta AB, Stockholm, Sweden).

**Methods:** Ten patients had computed tomography (CT), T2-weighted (T2W) and T2\*-weighted (T2\*W) magnetic resonance imaging (MRI) acquired. Three clinicians manually delineated the prostate for each imaging modality. Using the clinician contours, a simultaneous truth and performance level estimate (STAPLE) 'gold standard' atlas was created for each imaging modality.

Using the leave one out cross-validation method, ADMIRE was used to create prostate auto-contours with three, six and nine atlases, respectively. To minimise bias, atlases were chosen consecutively using scan date. Auto-contour accuracy by comparison to the gold standard was assessed with Dice similarity coefficient (DSC), Cohen's kappa, Hausdorff distance (HD) and mean distance between contours. Non-parametric Friedman testing was performed with Dunn's test for multiple comparisons.

**Results:** Using three atlases, median values for CT, T2W and T2\*W, respectively, were; DSC 0.85, 0.85, 0.87; Cohen's kappa 0.77, 0.78, 0.80; HD 11.6, 8.8, 10.2 mm; mean distance 2.1, 2.1, 1.9 mm; auto-contouring time 100, 24, 43 s. There is a significant difference between imaging modalities in auto-contouring time, although slice thickness was 1.5 mm for CT and 2.5 mm for MRI. There is no significant difference in accuracy between imaging types. There is a significant difference when increasing atlas numbers from three to nine for T2W (DSC, Cohen's, mean distance) and T2\*W (DSC, mean distance).

**Conclusion:** Auto-contours showed good agreement with clinician gold standard. Both increasing atlas numbers and differing modality impact auto-contouring time, with some evidence that increasing atlas numbers improves accuracy. Future research needs to assess clinical significance of such differences and identify ways to improve accuracy without time penalty.

#### References

- [1] Tao C-J, Yi J-L, Chen N-Y, Ren W, Cheng J, Tung S et al. Multi-subject atlas-based auto-segmentation reduces interobserver variation and improves dosimetric parameter consistency for organs at risk in nasopharyngeal carcinoma: a multi-institution clinical study. *Radiother Oncol* 2015;115:407–11.
- [2] Pathmanathan AU, van As NJ, Kerkmeijer LGW, Linda GW, Christodouleas J, Lawton CAF et al. Magnetic resonance imaging-guided adaptive radiation therapy: a "game changer" for prostate treatment? *Int J Radiat Oncol Biol Phys* 2018;100:361–73.

#### The National Radium-223 Dichloride Audit Group: Data from Patients in 17 UK Oncology Centres with Metastatic Castrate-resistant Prostate Cancer Treated with Radium-223 Dichloride

M. Randhawa\*, R. Jones\*, I. Stratton†, A. Bahl‡, D. Bottomley§, H. Carruthers||

\*The Beatson West of Scotland Cancer Centre, Glasgow, UK

†Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK

‡University Hospitals Bristol NHS Foundation Trust, Bristol, UK

§The Leeds Teaching Hospitals NHS Trust, Leeds, UK

||University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

**Purpose:** The National Radium-223 Dichloride Audit Group comprises clinicians from 17 oncology centres across the UK whose aim is to collect high-

quality data from patients with metastatic castrate-resistant prostate cancer (mCRPC) treated with radium-223 dichloride (Xofigo®).

**Methods:** Patients with mCRPC treated with radium-223 dichloride were identified and consented from September 2017 onwards. Demographics, clinical parameters such as primary treatment, date of diagnosis, ECOG performance status, weight, analgesic requirements, number of cycles completed, adverse events and Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaires were obtained, in addition to biochemical parameters, including full blood count, alkaline phosphatase, lactate dehydrogenase and prostate-specific antigen (PSA). These were recorded at baseline and follow-up visits prior to each treatment cycle.

**Results:** As of June 2018, data from 150 patients in 8 centres were available [presented as mean (standard deviation)]. Age at first treatment was 73 (8) years and weight was 85 (16) kg. Haemoglobin count was 125 (14) g/l, platelet count was 255 (75) × 10<sup>9</sup>/l and alkaline phosphatase level was 272 (316) U/l. PSA values [median (centiles)] were highly skewed, 86 (25th: 25; 75th: 177; 90th: 1070) µg/l. Preliminary follow-up data demonstrated that broad trends could be observed, such as increases in the prevalence of anaemia from 12% at baseline to 47% after completion of 6 cycles and in documented rates of fatigue from 53% to 84%.

**Conclusion:** The ongoing National Radium-223 Dichloride Audit is recording data from mCRPC patients treated across the UK in routine clinical care and to our knowledge is the first prospective analysis of such patients assessing quality of life outcomes in addition to standard biochemical and clinical parameters.

#### Validation and Reproducibility of Changes in Magnetic Resonance Imaging Radiomic Features in Response to Androgen Deprivation Therapy in Patients with High-risk Prostate Cancer

H. Tharmalingam\*†, W. Beasley†, R. Alonzi\*, A. McWilliam†, P. Hoskin\*†, A. Choudhury†

\*Mount Vernon Cancer Centre, Middlesex, UK

†The Christie NHS Foundation Trust, Manchester, UK

**Purpose:** Biochemical response to neoadjuvant androgen deprivation therapy (nADT) predicts recurrence-free and overall survival for prostate cancer (PCa). However, PSA levels often become undetectable following nADT and may not reflect the true extent of tumour cell kill. Our previous work on magnetic resonance imaging (MRI) of high-risk patients showed significant changes in textural radiomic features in response to nADT demonstrating their potential as surrogate biomarkers [1]. We aimed to validate these changes and evaluate their reproducibility using test–retest MRI scans before and after nADT.

**Methods:** 20 patients with high-risk PCa were examined with 4 MRI scans, 2 before nADT and 2 after 3 months of therapy. Median time between the first 2 scans was 2 days and between the last 2 was 1.5 days. T2-weighted sequences were used to define tumour regions-of-interest (ROI). These were subtracted from the prostate outline to form the benign prostate ROI. Pyradiomics, an open-source radiomics package, was used to extract textural features of homogeneity and energy from both ROI. A paired Student's *t*-test compared values before and after nADT. An inter-class correlation coefficient (ICC) calculated using mean feature values from consecutive MRI scans assessed reproducibility; an ICC value ≥ 0.85 considered high reproducibility.

**Results:** Baseline homogeneity and energy values differed between benign and malignant tissue ( $P < 0.0001$ ). In response to nADT, homogeneity and energy significantly increased in benign prostate (0.315–0.436,  $P = 0.0003$ ; 0.108–0.241,  $P < 0.0001$ , respectively) whilst decreasing in tumour (0.632–0.472,  $P = 0.0013$ ; 0.378–0.221,  $P = 0.0003$ ). Both features exhibited high reproducibility in benign and cancerous tissue before and after nADT; all ICC values ≥ 0.89.

**Conclusion:** Consistent with previous results, textural features of energy and homogeneity in benign and malignant prostate showed significant reciprocal changes in response to nADT. Validation of these feature changes and demonstration of their high reproducibility confirms their potential as prognostic biomarkers in high-risk PCa.

#### Reference

- [1] Tharmalingam H, Beasley W, McWilliam A, Van Herk M, Hambrook T, Padhani A et al. Changes in magnetic resonance imaging radiomic features in response to androgen deprivation therapy in patients with high-risk prostate cancer. *Eur J Surg Oncol* 2017;43(11):2231–2.